The CANTOS trial showed that canakinumab, an IL-1β inhibitor, significantly reduced major adverse cardiovascular events and mortality in stable atherosclerosis patients—but only in those with on-treatment IL-6 levels below 1.65 ng/L, highlighting IL-6 signaling as a critical mediator of cardiovascular benefit independent of lipid lowering [121]. This evidence concerns the gene IL6 and atherosclerosis.